Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like AmerisourceBergen Coughs Up $625M to Resolve U.S. Government Probe November 21, 2017 Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds November 21, 2017 SurModics Announces 2017 Annual Shareholders Meeting February 8, 2017
Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds November 21, 2017